194 related articles for article (PubMed ID: 19587549)
1. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
Mancia G; Unger T; Zanchetti A
J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
[No Abstract] [Full Text] [Related]
2. Cardiovascular protection: a breakthrough for high-risk patients?
Ferrari R
J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
[TBL] [Abstract][Full Text] [Related]
3. A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
Ritz E; Dahlöf B
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S1-2. PubMed ID: 18580859
[No Abstract] [Full Text] [Related]
4. ONTARGET: How much RAS inhibition is enough?
Weder AB
Curr Hypertens Rep; 2009 Feb; 11(1):7-9. PubMed ID: 19146793
[No Abstract] [Full Text] [Related]
5. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
Burnier M; Waeber B; Hess O; Lüscher T
Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
[No Abstract] [Full Text] [Related]
6. [The ONTARGET trial].
Verdecchia P; Terrosu P
G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
[No Abstract] [Full Text] [Related]
7. New clinical concepts after the ONTARGET trial.
Ruilope LM; Segura J; Zamorano JL
Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):685-9. PubMed ID: 21714599
[TBL] [Abstract][Full Text] [Related]
8. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
Sleight P
J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
[TBL] [Abstract][Full Text] [Related]
9. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
[No Abstract] [Full Text] [Related]
10. Focus on the ONTARGET results.
Elliott HL
J Hypertens Suppl; 2009 Jun; 27(2):S8-S10. PubMed ID: 19491625
[TBL] [Abstract][Full Text] [Related]
11. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
[No Abstract] [Full Text] [Related]
12. ARBs for cardiovascular and renal protection in high-risk patients.
Aalbers J
Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
[No Abstract] [Full Text] [Related]
13. Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
Weber M
J Hypertens Suppl; 2009 Jul; 27(5):S9-14. PubMed ID: 19587555
[TBL] [Abstract][Full Text] [Related]
14. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Böhm M; Baumhäkel M; Mahfoud F; Werner C
Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin system blockade and cardiovascular and renal protection.
Hoogwerf BJ
Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
[TBL] [Abstract][Full Text] [Related]
16. Where does the evidence lead us for the proper use of angiotensin II inhibitors in the management of cardiovascular disease?
Guthrie RM
Cardiology; 2010; 117(3):216-8. PubMed ID: 21160183
[No Abstract] [Full Text] [Related]
17. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
Ram CV; Deedwania PC
Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307
[No Abstract] [Full Text] [Related]
18. Telmisartan in high-risk cardiovascular patients.
Weber MA
Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
[TBL] [Abstract][Full Text] [Related]
19. [What is better here: ACE inhibitor or AT1 blocker?].
MMW Fortschr Med; 2008 Apr; 150(16):16-7. PubMed ID: 18557213
[No Abstract] [Full Text] [Related]
20. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
[No Abstract] [Full Text] [Related]
[Next] [New Search]
